China is setting the pace in embodied-AI capital — and the rounds keep getting bigger

The headline numbers are easy to misread as a bubble. By mid-May 2026, Chinese robotics and embodied-AI startups had raised roughly $5.6 billion across 176 deals, according to Crunchbase News — matching 2021's record year in under five months, and already past 2025's full-year total of about $4.3 billion. What makes this year different is not the total but the shape of it: nine-figure rounds have stopped being remarkable.

Nine figures is the new normal

The roster reads like a correction to anyone still treating embodied AI as early-stage. TARS Robotics opened with a $513 million seed. Spirit AI and Galaxea AI each stacked roughly $435 million across rounds. EngineAI raised a $200 million Series B; X Square Robot added a $293 million Series B on its way to a valuation above $2.8 billion. Against that backdrop, Zeroth's $74 million pre-Series A in July — a headline round in most markets — barely registers as mid-sized. When seed and Series A cheques clear half a billion dollars, the constraint on the sector is no longer capital. It is whether deployment can absorb it.

When a seed round clears half a billion dollars, capital is no longer the bottleneck. Deployment is. — EW analysis

The exit door is opening too

Private rounds only matter if there is somewhere for the money to go. In 2026 that exit is starting to appear onshore. Unitree Robotics filed in March to list on the Shanghai Stock Exchange, reportedly targeting a $3-7 billion valuation, and Robotphoenix listed in Hong Kong on May 18, raising about $86 million. A functioning IPO channel changes investor math: it shortens the path to liquidity and lets later rounds price against public comparables rather than hope. That, more than any single mega-round, is what turns a funding surge into a durable capital cycle.

Why it matters

The reflex read is that China is inflating a robotics bubble. The more useful read is that it is building the full stack of a capital market — large private rounds, strategic corporate backers and a domestic listing path — around a sector most of the world still files under research. Whether the deployments justify the valuations is the open question, and some of these numbers will not survive contact with revenue. But the direction is unambiguous: for embodied AI, the center of gravity in capital formation now runs through China, and the companies raising elsewhere are increasingly pricing against it.